AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $292.20 billion. The enterprise value is $348.13 billion.
Market Cap | 292.20B |
Enterprise Value | 348.13B |
Important Dates
The last earnings date was Friday, April 26, 2024, before market open.
Earnings Date | Apr 26, 2024 |
Ex-Dividend Date | Apr 12, 2024 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has decreased by -0.17% in one year.
Shares Outstanding | 1.77B |
Shares Change (YoY) | -0.17% |
Shares Change (QoQ) | -0.17% |
Owned by Insiders (%) | 0.11% |
Owned by Institutions (%) | 72.69% |
Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 49.09 and the forward PE ratio is 13.68. AbbVie's PEG ratio is 0.45.
PE Ratio | 49.09 |
Forward PE | 13.68 |
PS Ratio | 5.37 |
Forward PS | 5.11 |
PB Ratio | 36.49 |
P/FCF Ratio | 13.35 |
PEG Ratio | 0.45 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.51, with an EV/FCF ratio of 15.90.
EV / Earnings | 58.09 |
EV / Sales | 6.40 |
EV / EBITDA | 19.51 |
EV / EBIT | 37.83 |
EV / FCF | 15.90 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 9.24.
Current Ratio | 0.94 |
Quick Ratio | 0.72 |
Debt / Equity | 9.24 |
Debt / EBITDA | 4.15 |
Debt / FCF | 3.38 |
Interest Coverage | 5.47 |
Financial Efficiency
Return on equity (ROE) is 55.30% and return on invested capital (ROIC) is 12.43%.
Return on Equity (ROE) | 55.30% |
Return on Assets (ROA) | 4.30% |
Return on Capital (ROIC) | 12.43% |
Revenue Per Employee | $1.09M |
Profits Per Employee | $119,860 |
Employee Count | 50,000 |
Asset Turnover | 0.39 |
Inventory Turnover | 5.08 |
Taxes
In the past 12 months, AbbVie has paid $1.53 billion in taxes.
Income Tax | 1.53B |
Effective Tax Rate | 20.30% |
Stock Price Statistics
The stock price has increased by +14.39% in the last 52 weeks. The beta is 0.59, so AbbVie's price volatility has been lower than the market average.
Beta (1Y) | 0.59 |
52-Week Price Change | +14.39% |
50-Day Moving Average | 169.55 |
200-Day Moving Average | 158.38 |
Relative Strength Index (RSI) | 52.40 |
Average Volume (30 Days) | 5,615,056 |
Short Selling Information
The latest short interest is 14.48 million, so 0.82% of the outstanding shares have been sold short.
Short Interest | 14.48M |
Short Previous Month | 13.12M |
Short % of Shares Out | 0.82% |
Short % of Float | 0.82% |
Short Ratio (days to cover) | 2.60 |
Income Statement
In the last 12 months, AbbVie had revenue of $54.40 billion and earned $5.99 billion in profits. Earnings per share was $3.37.
Revenue | 54.40B |
Gross Profit | 33.88B |
Operating Income | 12.79B |
Pretax Income | 7.52B |
Net Income | 5.99B |
EBITDA | 17.85B |
EBIT | 9.20B |
Earnings Per Share (EPS) | $3.37 |
Balance Sheet
The company has $18.07 billion in cash and $74.00 billion in debt, giving a net cash position of -$55.93 billion or -$31.67 per share.
Cash & Cash Equivalents | 18.07B |
Total Debt | 74.00B |
Net Cash | -55.93B |
Net Cash Per Share | -$31.67 |
Equity / Book Value | 8.01B |
Book Value Per Share | 4.53 |
Working Capital | -2.65B |
Cash Flow
In the last 12 months, operating cash flow was $22.69 billion and capital expenditures -$795.00 million, giving a free cash flow of $21.89 billion.
Operating Cash Flow | 22.69B |
Capital Expenditures | -795.00M |
Free Cash Flow | 21.89B |
FCF Per Share | $12.38 |
Margins
Gross margin is 62.28%, with operating and profit margins of 23.50% and 11.02%.
Gross Margin | 62.28% |
Operating Margin | 23.50% |
Pretax Margin | 13.82% |
Profit Margin | 11.02% |
EBITDA Margin | 32.81% |
EBIT Margin | 16.91% |
FCF Margin | 40.24% |
Dividends & Yields
This stock pays an annual dividend of $6.20, which amounts to a dividend yield of 3.74%.
Dividend Per Share | $6.20 |
Dividend Yield | 3.74% |
Dividend Growth (YoY) | 4.84% |
Years of Dividend Growth | 52 |
Payout Ratio | 183.98% |
Buyback Yield | 0.17% |
Shareholder Yield | 3.92% |
Earnings Yield | 2.05% |
FCF Yield | 7.49% |
Analyst Forecast
The average price target for AbbVie is $180.55, which is 8.84% higher than the current price. The consensus rating is "Buy".
Price Target | $180.55 |
Price Target Difference | 8.84% |
Analyst Consensus | Buy |
Analyst Count | 12 |
Revenue Growth Forecast (5Y) | 5.71% |
EPS Growth Forecast (5Y) | 42.94% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 1.77 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.77 |
Piotroski F-Score | 5 |